Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifosfamide + mitomycin c
- Development stage
- Phase 2
- Lead developer
- NuGen Medical Devices
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination involves two chemotherapy drugs: **ifosfamide** and **mitomycin C**. **Ifosfamide** is an alkylating agent that works by adding an alkyl group to DNA, which interferes with DNA replication and transcription, leading to cell death. **Mitomycin C** is also an alkylating agent that cross-links DNA, preventing DNA replication and transcription, thus inhibiting tumor growth. This combination is used in treating various cancers, including non-small-cell lung cancer and metastatic pancreatic cancer.
- Other names
- Mitomycin and IfosfamideMI
02
Targets
DNA
Beyond the preview
Go deeper on ifosfamide + mitomycin c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifosfamide + mitomycin c.